eye openers
Monday, July 9, 7:30 – 8:15am
EO 1: Development of imaging probes and markers for biological characterization of tumors — Juri Gelovani, MDACC, Houston, USA
EO 2: Effects of track structure in radiation chemistry — Jay LaVerne, University of Notre Dame, USA
EO 3: Reassessment of effective dose of A-Bomb radiation and its possible impact on risk evaluation — Masao Sasaki, Kyoto University, Kyoto, Japan
EO 4: DNA repair foci: What are they and what are they good for? —Peggy L. Olive, BC Cancer Research Centre, Vancouver, Canada
Tuesday, July 10, 7:30 – 8:15am
EO 5: Target for Radiation cell kill: Rafts or DNA — Richard Kolesnick, MSKCC, New York, USA
EO 6: Heavy ion radiobiology in therapy and space — Marco Durante, University of Naples Federico II, Italy
EO 7: Low dose radiation exposure, polymorphisms and thyroid cancer risks — Alice Sigurdson, NCI, NIH, Bethesda, USA
EO 8: Targeted radiotherapy: Light at the end of the tunnel? — Rob Mairs, Beatson Institute of Cancer Research, Glasgow, UK
Wednesday, July 11, 7:30 – 8:15am
EO 9: Integration of data for systems biology — Michelle Buchanan, Oak Ridge National Lab, Oak Ridge, USA
EO 10: New mechanistic approaches to modeling radiation-induced cancer — Herwig Paretzke, GSF-National Research Center for Environment and Health, Neuherberg, Germany.
EO 11: The silent treatment: Delivering RNA interference. — Judy Lieberman, Harvard University, USA
EO 12: Novel radioprotectors — Roger Martin, Peter Mac Cancer Institute, Melbourne, Australia
Thursday, July 12, 7:30 – 8:15am
EO 13: Hematopoetic stem cells guide metastases — Ruth Muschel, Oxford University, Oxford, UK
EO 14: Nanoparticles in cancer and radiation biology — Gayle Woloschak, Northwestern University, Chicago, USA
EO 15: Understanding the chemistry of stored defense nuclear waste: Studies of waste stimulants. — Donald Camaioni, Pacific Northwest National Lab, Richland, USA
EO 16: The good and the bad of tumor suppression — Gerard Evan, UCSF, San Francisco, USA
|
